{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06233942",
            "orgStudyIdInfo": {
                "id": "BG-C9074-101"
            },
            "secondaryIdInfos": [
                {
                    "id": "2023-509958-65-00",
                    "type": "OTHER",
                    "domain": "EU CT Number"
                }
            ],
            "organization": {
                "fullName": "BeiGene",
                "class": "INDUSTRY"
            },
            "briefTitle": "Study of BG-C9074 as Monotherapy and in Combination With Tislelizumab in Participants With Advanced Solid Tumors",
            "officialTitle": "Phase 1a/1b Study of BG-C9074, an Antibody Drug Conjugate Targeting B7H4, as Monotherapy and in Combination With Tislelizumab in Participants With Advanced Solid Tumors",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "study-of-bg-as-monotherapy-and-in-combination-with-tislelizumab-in-participants-with-advanced-solid-tumors"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-04-12",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2027-09-28",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2027-09-28",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-01-23",
            "studyFirstSubmitQcDate": "2024-01-23",
            "studyFirstPostDateStruct": {
                "date": "2024-01-31",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-22",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-23",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "BeiGene",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": false
        },
        "descriptionModule": {
            "briefSummary": "This is a first-in-human, dose finding and dose expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-C9074 alone and in combination with tislelizumab in participants with advanced solid tumors. Participants will receive study drug(s) until progressive disease, unacceptable toxicity, withdrawal of consent, death, or another discontinuation criterion is met, whichever occurs first. The maximum length of receiving study drug(s) for a participant is up to 2 years."
        },
        "conditionsModule": {
            "conditions": [
                "Advanced Solid Tumor"
            ],
            "keywords": [
                "BG-C9074",
                "Tislelizumab",
                "Advanced Solid Tumors",
                "first-in-human",
                "B7H4"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 150,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Phase 1a: Part A (Monotherapy Dose Escalation)",
                    "type": "EXPERIMENTAL",
                    "description": "BG-C9074 monotherapy dose escalation",
                    "interventionNames": [
                        "Drug: BG-C9074"
                    ]
                },
                {
                    "label": "Phase 1a: Part B (Monotherapy Safety Expansion)",
                    "type": "EXPERIMENTAL",
                    "description": "BG-C9074 dose levels that have been determined to be safe and tolerable in Part A will be investigated.",
                    "interventionNames": [
                        "Drug: BG-C9074"
                    ]
                },
                {
                    "label": "Phase 1a: Part C (Combination Therapy Dose Escalation)",
                    "type": "EXPERIMENTAL",
                    "description": "BG-C9074 plus tislelizumab combination at the recommended dose for expansion (RDFE).",
                    "interventionNames": [
                        "Drug: BG-C9074",
                        "Drug: Tislelizumab"
                    ]
                },
                {
                    "label": "Phase 1b: Monotherapy Dose Expansion",
                    "type": "EXPERIMENTAL",
                    "description": "The monotherapy dose expansion phase will begin once the BG-C9074 monotherapy RDFE and dosing schedule have been determined from Parts A and B in Phase 1a.",
                    "interventionNames": [
                        "Drug: BG-C9074"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "BG-C9074",
                    "description": "administered by intravenous infusion",
                    "armGroupLabels": [
                        "Phase 1a: Part A (Monotherapy Dose Escalation)",
                        "Phase 1a: Part B (Monotherapy Safety Expansion)",
                        "Phase 1a: Part C (Combination Therapy Dose Escalation)",
                        "Phase 1b: Monotherapy Dose Expansion"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Tislelizumab",
                    "description": "administered by intravenous infusion",
                    "armGroupLabels": [
                        "Phase 1a: Part C (Combination Therapy Dose Escalation)"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Phase 1a: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)",
                    "description": "Number of participants with AEs and SAEs, including findings from physical examinations, electrocardiograms (ECGs), laboratory assessments, and that meet protocol-defined dose-limiting toxicity criteria.",
                    "timeFrame": "Approximately 3 years"
                },
                {
                    "measure": "Phase 1a: Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) of BG-C9074",
                    "description": "defined as the highest dose evaluated for which the estimated toxicity rate is closest to the target toxicity rate of 28% or the highest dose administered, respectively",
                    "timeFrame": "Approximately 18 months"
                },
                {
                    "measure": "Phase 1a: Recommended Dose for Expansion (RDFE) of BG-C9074.",
                    "description": "The potential RDFE(s) of BG-C9074 alone and in combination with tislelizumab will be determined based on the MTD or MAD, taking into consideration the long-term tolerability, PK, pharmacodynamics, preliminary antitumor activity, and any other relevant data, as available",
                    "timeFrame": "Approximately 18 months"
                },
                {
                    "measure": "Phase 1b: Overall Response Rate (ORR)",
                    "description": "ORR is defined as the percentage of participants with best overall response (BOR) of complete response (CR) or partial response (PR) assessed by the investigator using RECIST v1.1.",
                    "timeFrame": "Approximately 3 years"
                },
                {
                    "measure": "Phase 1b: Recommended Phase 2 dose (RP2D) of BG-C9074",
                    "description": "The RP2D of BG-C9074 will be determined based on safety, PK, pharmacodynamics, preliminary antitumor activity, and other relevant data, as available.",
                    "timeFrame": "Approximately 30 months"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Phase 1a: ORR",
                    "description": "ORR is defined as the percentage of participants with best overall response (BOR) of complete response (CR) or partial response (PR) assessed by the investigator using RECIST v1.1.",
                    "timeFrame": "Approximately 3 years"
                },
                {
                    "measure": "Duration of Response (DOR)",
                    "description": "DOR is defined as the time from the first determination of an objective response per RECIST v1.1 until the first documentation of disease progression or death, whichever occurs first as assessed by the investigator.",
                    "timeFrame": "Approximately 3 years"
                },
                {
                    "measure": "Disease Control Rate (DCR)",
                    "description": "DCR is defined as the percentage of participants with best overall response of CR, PR, or stable disease.",
                    "timeFrame": "Approximately 3 years"
                },
                {
                    "measure": "Clinical Benefit Rate (CBR)",
                    "description": "CBR is defined as the percentage of participants with best overall response of confirmed CR, PR, or stable disease lasting \u2265 24 weeks as assessed by investigator.",
                    "timeFrame": "Approximately 3 years"
                },
                {
                    "measure": "Phase 1b: Progression Free Survival (PFS)",
                    "description": "PFS is defined as the time from the date of the first dose of study drug(s) to the date of the first documentation of progressive disease assessed by the investigator using RECIST v1.1 or death, whichever occurs first.",
                    "timeFrame": "Approximately 3 years"
                },
                {
                    "measure": "Phase 1b: Number of Participants with AEs and SAEs",
                    "description": "Number of participants with AEs and SAEs, including findings from physical examinations, electrocardiograms (ECGs), laboratory assessments, and that meet protocol-defined dose-limiting toxicity criteria.",
                    "timeFrame": "Approximately 3 years"
                },
                {
                    "measure": "Maximum observed plasma concentration (Cmax) for BG-C9074",
                    "timeFrame": "Approximately 3 years"
                },
                {
                    "measure": "Minimum observed plasma concentration (Cmin) for BG-C9074",
                    "timeFrame": "Approximately 3 years"
                },
                {
                    "measure": "Time to maximum plasma concentration (Tmax) for BG-C9074",
                    "timeFrame": "Approximately 3 years"
                },
                {
                    "measure": "Half-life (t1/2) for BG-C9074",
                    "timeFrame": "Approximately 3 years"
                },
                {
                    "measure": "Area under the concentration-time curve (AUC) for BG-C9074",
                    "timeFrame": "Approximately 3 years"
                },
                {
                    "measure": "Apparent clearance (CL/F) for BG-C9074",
                    "timeFrame": "Approximately 3 years"
                },
                {
                    "measure": "Apparent volume of distribution (Vz/F) for BG-C9074",
                    "timeFrame": "Approximately 3 years"
                },
                {
                    "measure": "Accumulation ratio for BG-C9074",
                    "timeFrame": "Approximately 3 years"
                },
                {
                    "measure": "Plasma concentrations for BG-C9074",
                    "timeFrame": "Approximately 3 years"
                },
                {
                    "measure": "Number of participants with anti-drug antibodies (ADAs) to BG-C9074",
                    "timeFrame": "Approximately 3 years"
                },
                {
                    "measure": "Serum concentration of BG-C0974",
                    "timeFrame": "Approximately 3 years"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n1. Able to provide a signed and dated written informed consent prior to any study-specific procedures, sampling, or data collection.\n2. Eastern Cooperative Oncology Group (ECOG) Performance Status \u2264 1.\n3. Participants with selected histologically or cytologically confirmed advanced, metastatic, and unresectable solid tumors who have been previously treated.\n4. \u2265 1 measurable lesion per RECIST v1.1.\n5. Able to provide an archived tumor tissue sample.\n6. Adequate organ function.\n7. Females of childbearing potential must be willing to use a highly effective method of birth control for the duration of the study, and for \u2265 7 months after the last dose of study drug(s).\n8. Nonsterile males must be willing to use a highly effective method of birth control for the duration of the study treatment period and for \u2265 4 months after the last dose of study drug(s).\n\nExclusion Criteria:\n\n1. Prior treatment with a B7H4-targeting antibody drug conjugates (ADC)\n2. Active leptomeningeal disease or uncontrolled, untreated brain metastasis\n3. Any malignancy \u2264 2 years before the first dose of study treatment(s) except for the specific cancer under investigation in this study and any locally recurring cancer that has been treated with curative intent (eg, resected basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix or breast).\n4. History of interstitial lung disease, \u2265 Grade 2 noninfectious pneumonitis, oxygen saturation at rest \\< 92%, or requirement for supplemental oxygen at baseline\n5. Uncontrolled diabetes.\n6. Infection (including tuberculosis infection) requiring systemic (oral or intravenous) antibacterial, antifungal, or antiviral therapy \u2264 14 days before the first dose of study treatment(s).\n\nNote: Other protocol defined Inclusion/Exclusion criteria may apply.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Study Director",
                    "role": "CONTACT",
                    "phone": "1.877.828.5568",
                    "email": "clinicaltrials@beigene.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Study Director",
                    "affiliation": "BeiGene",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Florida Cancer Specialist Research Institute Lake Nona",
                    "status": "RECRUITING",
                    "city": "Orlando",
                    "state": "Florida",
                    "zip": "32827",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 28.53834,
                        "lon": -81.37924
                    }
                },
                {
                    "facility": "Sidney Kimmel Comprehensive Cancer At Johns Hopkins",
                    "status": "RECRUITING",
                    "city": "Baltimore",
                    "state": "Maryland",
                    "zip": "21287",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 39.29038,
                        "lon": -76.61219
                    }
                },
                {
                    "facility": "Macquarie University",
                    "status": "RECRUITING",
                    "city": "North Ryde",
                    "state": "New South Wales",
                    "zip": "2109",
                    "country": "Australia",
                    "geoPoint": {
                        "lat": -33.79677,
                        "lon": 151.12436
                    }
                },
                {
                    "facility": "Cancer Care Wollongong",
                    "status": "RECRUITING",
                    "city": "Wollongong",
                    "state": "New South Wales",
                    "zip": "2500",
                    "country": "Australia",
                    "geoPoint": {
                        "lat": -34.424,
                        "lon": 150.89345
                    }
                },
                {
                    "facility": "Monash Health",
                    "status": "RECRUITING",
                    "city": "Clayton",
                    "state": "Victoria",
                    "zip": "3168",
                    "country": "Australia",
                    "geoPoint": {
                        "lat": -37.91667,
                        "lon": 145.11667
                    }
                },
                {
                    "facility": "Peter Maccallum Cancer Centre",
                    "status": "RECRUITING",
                    "city": "Melbourne",
                    "state": "Victoria",
                    "zip": "3000",
                    "country": "Australia",
                    "geoPoint": {
                        "lat": -37.814,
                        "lon": 144.96332
                    }
                },
                {
                    "facility": "Linear Clinical Research",
                    "status": "RECRUITING",
                    "city": "Nedlands",
                    "state": "Western Australia",
                    "zip": "6009",
                    "country": "Australia",
                    "geoPoint": {
                        "lat": -31.98184,
                        "lon": 115.8073
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "C000707970",
                    "term": "Tislelizumab"
                }
            ],
            "ancestors": [
                {
                    "id": "D000074322",
                    "term": "Antineoplastic Agents, Immunological"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M4225",
                    "name": "Antibodies",
                    "relevance": "LOW"
                },
                {
                    "id": "M137899",
                    "name": "Tislelizumab",
                    "asFound": "Nerve block",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10184",
                    "name": "Immunoglobulins",
                    "relevance": "LOW"
                },
                {
                    "id": "M1346",
                    "name": "Antineoplastic Agents, Immunological",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                }
            ]
        }
    },
    "hasResults": false
}